News

ERT is a technology-driven provider of health outcomes services to biopharmaceutical sponsors and contract research organizations to achieve their drug development and healthcare objectives. ERT CEO Jeffrey Litwin

Upon the conclusion of the agreement, AnGes will earn upfront payments and milestone payments. AnGes expects to maximize the asset value of Collategene by conducting a prompt global

The company proposed the injection for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole. ThromboGenics CEO Patrik De Haes said that the FDA has granted ocriplasmin

Mylan gained final FDA approval for its abbreviated new drug application for Desloratadine Tablets, 5mg, and is shipping the product immediately. According to IMS Health, Desloratadine Tablets, 5mg,

The particulate matter, which has been recognized as a potential health hazard, was identified as active drug substance and not foreign material or contamination. Vein irritation and phlebitis,

According to ThermoGenesis, the payment is due during the company’s first fiscal quarter of 2013. ThermoGenesis chief executive officer Matthew Plavan said the divestiture is an important milestone

The international, multicentre, randomised trial will evaluate the safety and efficacy of lucanthone administered in combination with temozolomide (TMZ) and radiation treatment. Spectrum Pharmaceuticals chairman, president and chief

With the additional funding, the total contract is now valued at CA$7.7m ($7.6m). In the next development phase, the company will enhance the capability of the original solution,

The Extedo solution will validate, import, and review electronic submission information sent by pharmaceutical companies on electronic media such as CDs or DVDs. Extedo CEO Tore Bergsteiner said